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Abstract
Esophageal Barrett’s adenocarcinoma (BA) develops
through a multistage process, which is associated
with the transcriptional silencing of tumor-suppressor
genes by promoter CpG island hypermethylation. In
this study, we explored the promoter hypermethyla-
tion and protein expression of proapoptotic death-
associated protein kinase (DAPK) during the multistep
Barrett’s carcinogenesis cascade. Early BA and paired
samples of premalignant lesions of 61 patients were
analyzed by methylation-specific polymerase chain re-
action and immunohistochemistry. For the association
of clinicopathological markers and protein expression,
an immunohistochemical tissue microarray analysis
of 66 additional BAs of advanced tumor stages was
performed. Hypermethylation of DAPK promoter was
detected in 20% of normal mucosa, 50% of Barrett’s
metaplasia, 53% of dysplasia, and 60% of adenocarci-
nomas, and resulted in a marked decrease in DAPK
protein expression (P < .01). The loss of DAPK pro-
tein was significantly associated with advanced depth
of tumor invasion and advanced tumor stages (P <
.001). Moreover, the severity of reflux esophagitis cor-
related significantly with the hypermethylation rate
of the DAPK promoter (P < .003). Thus, we consider
DAPK inactivation by promoter hypermethylation as
an early event in Barrett’s carcinogenesis and sug-
gest that a decreased protein expression of DAPK
likely plays a role in the development and progression
of BA.
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Introduction
The incidence of Barrett’s adenocarcinoma (BA) has increased
rapidly in the western world over the past three decades [1,2].
Barrett’s carcinogenesis is a multistep process composed of
genetic and epigenetic alterations in mismatch repair genes,
tumor-suppressor genes, cell cycle regulator genes, proto-
oncogenes, tissue invasion–related genes, or genes essential
for cell–cell adhesion [3,4]. Progressive accumulation of gene
alterations is postulated for the transition of normal squamous
epithelium to metaplastic specialized columnar epithelium
[Barrett’s metaplasia (BE)] and subsequently through Barrett’s
dysplasia (DYS) to BA [2]. BE represents the most serious
histologic consequence of chronic gastroesophageal reflux.
It develops in 5% to 10% of patients with gastroesophageal
reflux disease [5] and shows an incidence of malignant
transformation between 0.2% and 2% each year [3]. Pro-
longed chronic inflammation in gastric reflux may contribute
to Barrett’s carcinogenesis through mechanisms of repetitive
tissue damage and regeneration in the presence of reactive
phagocyte-derived oxygen and nitrogen species. Locally pro-
duced cytokines and acids in the refluxate create a microenvi-
ronment that sets the scene for metaplastic and neoplastic
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transformations of the esophageal epithelium, mainly by di-
rectly affecting metaplastic stem cells [2]. It has been postu-
lated that gastric reflux has epigenetic, rather than genotoxic,
effects on esophageal transdifferentiation [6]. Indeed, hyper-
methylation of various genes is a very common event in
BA and occurs as early as metaplasia [3,7–13], which
supports the precancerous nature of Barrett’s specialized
intestinal metaplasia.
Death-associated protein kinase (DAPK) is an actin-
associated calcium/calmodulin–dependent enzyme with
serine/threonine kinase activity [14–16]. DAPK is involved
in tumor necrosis factor-a and Fas-induced apoptosis, and
has been demonstrated to be an essential mediator in
IFN-g–induced programmed cell death [17]. Furthermore,
its proapoptotic function was found to be associated with
p19ARF/p53–mediated apoptosis in the rodent model [18].
As disruption of processes involved in programmed cell
death is a common feature of human cancers, it is sig-
nificant that inactivation of DAPK by hypermethylation in
the promoter CpG region has been described in a variety
of human tumors, including gastrointestinal malignancies,
such as carcinomas of the colorectum [19–22], anus [23],
esophagus, esophagogastric junction, and stomach [24–
28]. DAPK suppresses tumor growth and metastasis by
increasing the occurrence of apoptosis in vivo [29]. Loss of
DAPK expression is associated with poor overall survival
rates of cancer patients (e.g., in primary biliary tract car-
cinoma and non–small cell lung carcinoma) [30,31].
Because alterations of proapoptotic genes might cause
instability in the balance of cell turnover during the chronic
inflammatory processes of reflux esophagitis and BE, epi-
genetic silencing of DAPK might be involved in the early
stages of Barrett’s carcinogenesis. Although epigenetic
changes of the DAPK promoter have been recognized in
BA [25,26], data regarding epigenetic abnormalities in its
premalignant lesions are limited.
To determine the impact of hypermethylation during multi-
step Barrett’s carcinogenesis, we analyzed the promoter
hypermethylation and protein expression of DAPK in non-
tumorous esophageal squamous mucosa (NT), Barrett’s
intestinal metaplasia, dysplasia of Barrett’s mucosa, and
adenocarcinoma.
Materials and Methods
Patients and Tissue Samples
Specimens of non-neoplastic and neoplastic esophageal
tissues analyzed in this retrospective study were obtained
from two principal sources. First, formalin-fixed paraffin-
embedded specimens consisting of 35 BA, 28 BE, 14 low-
grade dysplasia, 7 high-grade dysplasia, and 20 samples of
nondysplastic esophageal squamous mucosa (NT) were
analyzed by methylation-specific polymerase chain reaction
(MSP) and immunohistochemistry. The specimens were
obtained from mucosal and surgical resections from 61
patients at the archives of the Institutes of Pathology, Bay-
reuth and Magdeburg, Germany. This group had an average
age of 63.7 years (range, 43–79 years) and consisted of
53 males and 8 females. Twenty-six of 35 BA (74%) repre-
sented mucosal carcinoma or carcinoma of early tumor
stages (Table 1). Second, formalin-fixed paraffin-embedded
specimens of BA and paired noncancerous esophageal mu-
cosa of 66 patients who had undergone surgery at the Uni-
versity of Virginia were submitted to immunohistochemical
tissue microarray analysis. This study group comprised
57 male and 9 female patients ranging in age from 51 to
79 years (median, 64.5 years) and included carcinomas of
advanced tumor stages (Table 2).
Histopathological diagnosis was verified by examining
hematoxylin/eosin–stained slides without any knowledge
of clinical data (D.K., M.S., and M.V.). Grading of dysplasia,
as well as the staging and grading of adenocarcinomas,
was performed according to the recent guidelines of the
International Union Against Cancer (UICC) Tumor–Node–
Metastasis (TNM) classification system [32]. The severity of
reflux esophagitis was estimated according to Vieth et al.
[33]. The study has been approved by the locally appointed
ethics committee and is in accordance with the guidelines of
the Declaration of Helsinki for biomedical research. Informed
consent was obtained from all patients included in this study.
Tissue Microarray
Representative regions of carcinoma and paired nor-
mal esophageal mucosa were selected from hematoxylin/
eosin–stained slices for inclusion in a tissue array. Tissue
cores with a diameter of 0.6 mm were retrieved from se-
lected regions of donor blocks and punched to a recipient
block using a manual tissue array instrument (Beecher
Instruments, Silver Spring, MD). Samples were punched in
triplicate. The resulting tumor tissue array was used for im-
munohistochemistry analysis.
DNA Preparation and MSP
After identifying and marking the lesions of interest on
hematoxylin/eosin–stained sections (D.K. and M.V.), mirror-
imaged areas on 10-mm-thick paraffin-embedded tissue sec-
tions were separated macroscopically or, if necessary, by
laser capture microdissection (PALM, Bernried, Germany).
DNA was prepared using the NucleoSpin Tissue Kit
(Macherey and Nagel, Dueren, Germany).
For detection of promoter methylation status, MSP was
performed as described recently [22]. Briefly, extracted
DNA was subjected to sodium bisulfite modification using
the CpGenome DNA modification kit (Intergen, Purchase,
NY). Modified DNA was subjected to MSP using specific
primers for methylated sequences (sense 5V-GGATAGTC-
GGATCGAGTTAACGTC-3V and antisense 5V-CCCTCCCA-
AACGCCGA-3V) and for unmethylated sequences (sense
5V-GGAGGATAGTTGGATTGAGTTAATGTT-3V and anti-
sense 5V-CAAATCCCTCCCAAACACCAA-3V), which gener-
ates polymerase chain reaction (PCR) products of 114 and
116 bp, respectively. The total 25 ml of PCR mix contained
2 ml of bisulfite-modified DNA, 1 PCR buffer, 3 mM MgCl2,
12.5 pmol of each primer, 160 mM dNTPs, and 0.5 U of Hot-
Goldstar Taq polymerase (Eurogentec, Seraing, Belgium).
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PCR conditions were as follows: 95jC for 10 minutes, 35 cy-
cles of 95jC for 1 minute, annealing with 60jC for 1 minute
and 72jC for 1 minute, followed by a final extension step at
72jC for 10 minutes. Methylated standard DNA (Intergen)
was used as a positive control for methylation, and placenta
DNA was used as a negative control. PCR products were
electrophoresed on polyacrylamide gels and visualized by
silver staining.
Immunohistochemistry
DAPK protein expression was immunohistochemically
analyzed for BE, DYS, BA, and normal esophageal squa-
mous mucosa of all cases investigated by MSP, as well
as for the tissue microarray of BA and corresponding NT.
For identifying DAPK-expressing cells, five methylated and
five unmethylated adenocarcinoma samples were addition-
ally investigated using CD68 antibody. CD68 is a 110-kDa
transmembrane glycoprotein associated with lysosomes
and is therefore used as a common marker of cells of the
monocyte–macrophage lineage, including tissue macro-
phages. Formalin-fixed paraffin-embedded serial tissue sec-
tions (3 mm thick) were dewaxed in xylol and rehydrated
by descending concentrations of ethanol. Slices were sub-
jected to antigen retrieval using microwave heating (20 min-
utes, 450 W, 10 mM EDTA pH 8.0), followed by incubation
with specific primary antibodies recognizing DAPK (rabbit
polyclonal antibody 44-672, dilution 1:200; BioSource Inter-
national, Inc., Camarillo, CA) and CD68 (mouse monoclonal
antibody M0814, dilution 1:400; DAKO, Hamburg, Germany),
Table 1. PCR-Specific Promoter Methylation Pattern of DAPK according to
Histopathological Diagnosis and Clinical Characteristics.
Samples Sex/Age
in Years
pTNM Grading Reflux Methylation Pattern
NT BE LDys HDys BA
B01 M/63 2 Un
B02 M/66 1 Un
B03 M/43 1 Un Un
B04 M/71 T1N0Mx 1 1 Un Un
B05 M/70 T1N0Mx 3 3 Un Un
B06 F/69 T1N0Mx 1 2 Un
B07 M/73 T1N0Mx 2 1 Un
B08 M/72 T1N0Mx 2 1 Un Un
B09 M/67 T1N0Mx 1 1 Un Un
B10 M/77 1 Un Un
B11 M/78 T1N0Mx 1 2 Un Un
B12 M/58 T1N0Mx 1 2 Un Un
B13 M/49 T1N0Mx 1 2 Un Un
B14 M/59 T1N0Mx 1 1 Un Un
B15 M/72 T1N0Mx 2 1 Un Un Un
B16 M/75 T1N0Mx 1 1 Un Un
B17 F/70 T1N0Mx 1 2 Un
B18 F/70 T1N0Mx 1 2 Un
B19 M/61 T1N0Mx 1 1 Un
B20 M/65 T1N0Mx 2 0 Un
B21 M/69 T1N0Mx 1 1 Un
B22 M/69 T1N0Mx 1 1 Un
B23 M/64 T1N1M1 3 0 Un
B24 M/62 T3N1M1 3 0 Un
B25 M/64 T3N1M0 2 0 Un
B26 M/60 T3N1M1 3 0 Un
B27 F/72 1 Met
B28 M/71 T4N1M0 3 3 Met
B29 M/46 3 Met
B30 F/50 3 Un Met
B31 M/74 T1N0Mx 1 1 Un Met
B32 M/50 1 Met
B33 F/54 3 Met
B34 M/67 T1N0Mx 2 2 Met
B35 M/62 1 Un Met Met
B36 M/64 T1N0Mx 1 1 Un Met Met
B37 M/71 T4N1M0 3 3 Un Met Met Met
B38 M/60 1 Met
B39 M/64 2 Met
B40 M/49 T1N0Mx 1 2 Met
B41 M/66 T2N1M0 3 2 Met
B42 M/69 T2N0M0 2 2 Met
B43 M/73 T1N0Mx 1 2 Met
B44 F/69 T1N0Mx 2 3 Met
B45 M/57 T1N0Mx 3 3 Met
B46 M/69 T1N0M0 2 3 Met
B47 M/65 T3N1M0 3 3 Met
B48 M/79 T1N0Mx 1 2 Un Met
B49 M/49 T1N0Mx 1 2 Un Met
B50 M/68 T1N0M0 2 2 Un Met
B51 M/71 T1N0Mx 2 3 Un Un Met
B52 M/70 T1N0Mx 3 3 Un Met Met
B53 M/51 2 Un Un Met
B54 M/51 T1N0M0 1 2 Un Un Met Met
B55 M/59 T1N0M0 1 3 Met Met
B56 F/65 T3N0M1 2 3 Met Met
B57 M/60 3 Met Met
B58 M/48 T1N0Mx 1 2 Met Met Met
B59 M/75 T1N0M0 1 3 Met Met Met
B60 M/50 T1N0Mx 1 3 Met Met
B61 F/53 T1N0Mx 1 3 Met Met
Methylation analysis of DAPK promoter in esophageal tissues from 61 pa-
tients, including nondysplastic esophageal squamous mucosa (NT), BE, low-
grade and high-grade dysplasias of Barrett’s mucosa (LDys and HDys,
respectively), and BA.
pTNM = postsurgical histopathological tumor classification; reflux = severity
of gastroesophageal reflux obtained by histologic criteria; Un = unmethylated
samples; Met = methylated samples.
Table 2. Analysis of Immunohistochemical DAPK Protein Expression and
Clinicopathological Features of Advanced BAs.




64.3 ± 6.53 63.3 ± 10.55 62.7 ± 6.65 .947*
Sex
Male 14 30 13 .296y
Female 1 5 0
Tumor differentiation
Mild 0 5 2 .127y
Moderate 2 14 5
Poor 13 17 8
Depth of invasion
pT1, pT2 0 20 13 .000y
pT3, pT4 15 16 2
Lymph node metastasis
Negative 10 30 14 .157y
Positive 5 6 1
Lymph invasion
Negative 4 17 10 .090y
Positive 11 19 35
Metastasis
Negative 11 34 14 .071y
Positive 4 2 1
Stage
I, II 3 26 14 .001y
III, IV 12 10 1
Correlation of clinicopathological markers and immunohistochemical protein
expression of DAPK in a tissue microarray of 66 advanced BAs.
IRS = immunoreactive score, merged into three groups for statistical ana-
lyses (0–3, 4–8, and 9–12 points).
*One-way analysis ANOVA.
yChi-square test.
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respectively, at 37jC for 30minutes. After phosphate-buffered
saline (PBS) washing, incubation with biotinylated secondary
antibody was conducted (anti-mouse IgG, anti-rabbit IgG,
dilution 1:200; Vector Laboratories, Burlingame, CA) at room
temperature for 30 minutes. Detection of the bound antibody
was accomplished using the avidin–biotin complex method
(Vectastain Elite ABC Kit; Vector Laboratories). A 0.1% solu-
tion of 3,3V-diaminobenzidine (5 minutes; Sigma, St. Louis)
was used as chromogen. Specificity of immunostaining was
checked by omitting single steps in the immunohistochemical
protocol and by replacing the primary antibody with nonim-
mune serum. Positive tissue controls that were stained in par-
allel with test slides included sections of normal colon mucosa.
Triple Immunofluorescence Analysis
Double labeling of DAPK/CD68 was performed in five rep-
resentative cases for each methylated and unmethylated ade-
nocarcinoma. Tissue sections were deparaffinized in xylene
and dehydrated in ethanol, followed by standard antigen re-
trieval (microwave, 1 mM EDTA). Nonspecific reactions were
blocked with 10% horse serum/PBS. We used specific anti-
bodies as primary antibodies recognizing DAPK and CD68,
as described above. Incubation was performed separately
for each antibody at 4jC for 16 hours. After washing with
PBS and Triton, primary antibodies were detected with FITC-
conjugated anti-rabbit antibody and Texas red–conjugated
anti-mouse antibody, respectively (dilution 1:100, each for
2 hours, at 37jC; Vector Laboratories). Counterstaining and
mounting were performed in Vectashield mounting medium
with DAPI (Vector Laboratories). Analysis was performed
using a fluorescence microscope (Leica DMRE7; Leica
Wetzlar, Germany) equipped with a charge-coupled device
camera (SPOT RT; Diagnostic Instruments, Burroughs, MI).
Separate images were taken in corresponding channels and
merged using the SPOT Advanced software (Diagnostic
Instruments). Image acquisition of controls and data pro-
cessing were performed under the same conditions.
Semiquantitative Assessment of
Immunohistochemical Results
For DAPK protein expression, staining intensity (SI; 1 =
weak, 2 = moderate, 3 = strong) and the percentage of
positive cells (PC; 1 = < 10%, 2 = 10–50%, 3 = 51–80%,
4 = > 80%) were semiquantitatively assessed, resulting in an
immunoreactive score (IRS = SI  PC) with a maximum of
12 points. The average immunoreactive score was finally
estimated for each group. Scoring was performed for the
tumor epithelium and stromal macrophages. Immunoreac-
tivity for CD68 was scored as positive or negative, depending
on the presence or the absence of cytoplasmatic immuno-
reactivity. To determine the index of DAPK-expressing mac-
rophages, DAPK-labeled cells per CD68+ stromal cells were
counted in 20 high-power fields of tumor adjacent stroma.
Samples were examined by two independent pathologists
(D.K. and M.V.) who were blinded to other data.
Statistical Analysis
For group comparison, samples with low-grade and high-
grade dysplasias were pooled in one group containing all
cases with dysplasia (DYS). For statistical analysis, patients
were merged into three groups, depending on the immunore-
active score of DAPK estimated by immunohistochemistry
(IRS of 0–3, 4–8, and 9–12 points, respectively). For clini-
copathological correlation, we merged the TNM and pT
categories into early stage (V stage II; V pT2) and late stage
(z stage III; > pT3), and the association of protein expression
with TNM stage was investigated using chi-square tests.
Correlation between variables was estimated using Fisher’s
exact test. The linear association between the methylation of
DAPK promoter and the average immunoreactive score for
DAPK was determined by Pearson’s coefficient. For descrip-
tive data analysis and all statistical tests, SPSS software 11.5
for Windows (Chicago, IL) was used. A two-sided value of
P V .05 was considered statistically significant.
Results
DAPK Promoter Methylation Presents as an Early
Event in Barrett’s Carcinogenesis
Figure 1A shows representative examples of MSP analy-
sis. Figure 1B summarizes the promoter hypermethylation
frequency of DAPK in different groups of esophageal tissue
samples. DAPK was hypermethylated in both non-neoplastic
Figure 1. Results of MSP analysis of the DAPK promoter. (A) Representative MSP results of the DAPK promoter of three patients (B31, B55, and B51), including
samples of nontumorous squamous epithelium (NT), Barrett’s mucosa (BE), high-grade dysplasia (HDys), and BA. Lane un: unmethylated PCR product. Lane m:
methylated PCR product. (B) Frequency of hypermethylation of the DAPK promoter in nontumorous, premalignant, and malignant esophageal tissues. Each bar
illustrates the portion of samples of a certain lesion classified as ‘‘hypermethylated.’’
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and neoplastic samples, with a significant increase in meth-
ylation frequency from nondysplastic esophageal squamous
cell mucosa to BE. BE without evidence of dysplasia/
neoplasia exhibited methylated DAPK in 14 of 28 (50%)
cases. In corresponding esophageal squamous cell epithe-
lium, hypermethylation was detected in 4 of 20 cases (20%).
Furthermore, MSP of DAPK revealed that 21 of 35 (60%) BA
and 11 of 21 (53%) Barrett’s mucosa with low-grade and
high-grade DYS showed aberrant methylation at the CpG
island. The difference between the methylation frequency
of normal-appearing squamous mucosa and that of BE,
DYS, or BA, respectively, proved to be statistically significant
(P < .01). Furthermore, the transition from BE to IN or BA
was associated with a further increase in DAPK gene meth-
ylation but did not reach statistical significance. An unmeth-
ylated PCR product and a methylated PCR product were
detected in all methylated samples suggesting monoallelic
DAPK promoter hypermethylation. Biallelic methylation was
never observed.
Hypermethylation of DAPK Is Associated with Severity
of Reflux Esophagitis
Statistical analysis of the correlation of methylation status
and clinical and demographic characteristics revealed no
significant correlations for the frequency of DAPK hyper-
methylation and patient age or gender and tumor grading
[P = .16, P = .29, and P = .13, respectively; one-way analy-
sis of variance (ANOVA) and Fisher’s exact test]. Because
26 of 35 carcinomas investigated by MSP were early carci-
nomas, a correlation of methylation frequency with tumor
stage could not be established. By contrast, the severity of
reflux esophagitis, scored by histologic criteria, was signifi-
cantly associated with DAPK promoter hypermethylation
(P < .003; Fisher’s exact test) (Table 1).
DAPK Promoter Methylation Correlates with Loss
of Protein Expression
Examples of immunohistochemical protein expression of
DAPK in esophageal tissue samples are given in Figures 2
and 3. In cases exhibiting no methylation, cytoplasmatic
staining with moderate to strong intensity of immunore-
activity was observed. As expected, we found a significant
correlation between DAPK methylation and decrease in
immunoreactivity within the non-neoplastic, metaplastic,
and dysplastic epithelia (P < .01) (Figure 2). In the group
of methylated lesions, the epithelium of each of the samples
with BE and low-grade DYS, as well as three cases of BA,
appeared to be completely immunonegative. Heterogeneous
DAPK expression in dysplastic and neoplastic tissues was
not observed.
Loss of DAPK Protein Expression Correlates
with Progressively Advanced Stages of Disease
Because the group of BA investigated by MSP consisted
mostly of early carcinomas, data correlated with DAPK pro-
tein expression in a tissue microarray of 66 additional
BAs with heterogeneous clinicopathological characteristics
(Table 2, Figure 3). Statistical analysis revealed a significant
loss of protein expression with tumor invasion depth (aver-
age IRS: pT1/pT2 = 9.9/8.45 vs pT3/pT4 = 5.7/4.1; P < .001)
(Figure 4A). Significant loss of protein expression was ob-
served for early-stage tumors compared to nondysplastic
squamous epithelium (average IRS = 9.9. vs 11.3; P < .01).
Furthermore, there was a significant lower DAPK protein
expression in tumor stages III and IV relative to less ad-
vanced tumors in stages I and II (average IRS = 9.33 and 7.7
vs 4.4 and 5.12; P < .001) (Figure 4B). There were no
significant correlations of immunohistochemically estimated
DAPK protein expression with gender, age, tumor differenti-
ation, and lymph node metastasis (Table 2).
Tumor-Associated Macrophages Express DAPK Protein
and Are Rarely Detectable in Cases of Adenocarcinoma
with DAPK Hypermethylation
In all unmethylated samples of BE, DYS, and BA, we
noted strong immunohistochemical reactivity for a group of
inflammatory cells of the surrounding stroma. An immuno-
histochemical analysis of the DAPK and CD68 protein
expressions of serial slices revealed a concordant expres-
sion pattern of both proteins. Using triple immunofluores-
cence, DAPK-expressing stromal cells were identified as
macrophages (Figure 5, A and B). Interestingly, DAPK-
positive macrophages were accentuated at the tumor inva-
sion front of unmethylated carcinoma, whereas only a minor
fraction of the macrophages expressed DAPK in cases with
promoter methylation and decreased protein expression
(Figure 5C ). The differences in the expression pattern of
the macrophages between methylated and unmethylated BA
proved to be statistically significant (P < .01).
Discussion
Whereas aberrant methylation of the DAPK promoter has
been reported frequently in early preneoplastic lesions of the
gastrointestinal tract, such as in the colon, stomach, and
anus [19,20,22,23,27,28], studies of DAPK inactivation in
esophageal tissue have focused primarily on BA so far [24–
26]. Here, we report a study on the promoter methylation
status and protein expression of DAPK in matched samples
of nondysplastic esophageal squamous epithelium, BE, low-
grade and high-grade DYS, and BA of 127 patients. To our
knowledge, this is the most comprehensive methylation
study of DAPK ever performed, involving so many distinct
histologic stages of disease progression in Barrett’s carcino-
genesis. Hypermethylation of the promoter region of the
DAPK gene occurred in a high percentage of BA (60%)
and could be detected in precursor lesions as well (53% for
DYS and 50% for BE, respectively). A significant difference
in methylation frequency between NT (20%) and BE was
established (P < .01). There was a tendency toward the
accumulation of DAPK promoter methylation in the Barrett
carcinogenesis model. Interestingly, loss of DAPK protein
expression was associated with advanced tumor invasive-
ness and tumor stage.
Eads et al. [10] postulated that DNA hypermethylation is
an early epigenetic alteration in Barrett’s carcinogenesis.
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Epigenetic studies of the model of Barrett’s carcinogenesis
with regard to preneoplastic lesions have been limited to the
DNA methylation analysis of a few different genes. Similar to
our study, these analyses reported an accumulation of hyper-
methylation events for genes such as CDKN2A/p16INK4a,
GPX, TIMP3, RUNX3, and HPP1 along Barrett’s carcino-
genesis, whereas the timing and the frequency of hyper-
methylation varied according to gene [7,8,10,12,13].
The methylation of CpG islands located within the pro-
moter element is generally associated with a decrease in
protein expression or a loss of protein expression [34,35].
In fact, in this study, the occurrence of DAPK promoter
Figure 2. Immunohistochemical analysis for the protein expression of DAPK in methylated and unmethylated esophageal tissues representative of non-neoplastic,
metaplastic, and neoplastic alterations. Methylation of DAPK promoter resulted in decreased and partial loss of DAPK protein expression (original magnification,
10 and 40). Nontumorous esophageal squamous cell epithelium: unmethylated (A), methylated (B); BE: unmethylated (C), methylated (D); dysplasia of
Barrett’s mucosa: unmethylated (E), methylated (F); BA: unmethylated (G), methylated (H).
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Figure 3. Tissue microarray of BA. Immunohistochemical analysis of DAPK protein expression was conducted on a tissue microarray consisting of 66 BA and
corresponding esophageal squamous mucosa specimens (original magnification, 1 and 20). Overview of the tissue microarray slide (A). DAPK-positive sample
of non-neoplastic squamous mucosa (B). Examples of tissue microarray core with well-differentiated carcinoma and strong DAPK protein expression (C);
moderately differentiated carcinoma and moderate protein expression (D); and poorly differentiated carcinoma with weak protein expression (E).
Figure 4. Correlation between immunohistochemical analysis of DAPK protein expression and clinicopathological data. Immunohistochemical protein expression
of DAPK was significantly altered depending on tumor invasiveness (pT) (A) and tumor stage (B). A marked decrease in DAPK protein expression correlates with
progressively advanced stages of tumor disease.
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hypermethylation correlated strongly with a marked decrease
in protein expression. Furthermore, for some methylated
cases, a complete absence of DAPK protein expression
was demonstrated, even though biallelic methylation was
never observed by PCR. In these cases, accompanying
unmethylated PCR products might be the result of contami-
nation with inflammatory cells and surrounding stroma. This
strong association between promoter hypermethylation and
loss of the protein expression of DAPK suggests that hyper-
methylation may be the main inactivation mechanism of this
gene in BA and its precursor lesions.
Furthermore, our observation that hypermethylation
and loss of DAPK protein expression were already present
in BE and DYS and in four cases of NT, and the lack of
a significant difference in methylation frequency between
BE and DYS or BA suggest that hypermethylation of the
DAPK promoter may be an early acquired epigenetic event
in the tumorigenic process of BA. DAPK hypermethylation
as an early event of gastrointestinal malignancies and its
precursor lesions has already been reported for gastric and
colorectal carcinomas [20,22,27] and indicates that the im-
pairment of the proapoptotic function of DAPK could be
important in malignant transformation.
Two biologic issues have been identified in the carcino-
genesis of BA: the balance between cell proliferation and
apoptosis in determining the clonal expansion of metaplastic
or malignant cells, and the role of altered cell adhesion in
remodeling inflamed BE [3]. The development of Barrett’s
esophagus represents an acquired response to gastro-
esophageal reflux, thereby providing greater resistance to
the effects of chronic mucosal inflammation. DAPK might be
involved in the repair process of mucosal damage mediated
by gastroesophageal reflux and caused by chronic inflam-
mation. Here, the kinase could function as a caretaker gene
by inducing apoptosis, thus eliminating premalignant cells in
chronically inflamed and damaged esophageal mucosa.
Until now, it has not been shown mechanistically that bile
or acid modulates chromatin-modifying enzymes and is
capable of inducing hypermethylation of genes. It should
be interesting to investigate in a future study whether there is
an association between high acid exposure and DAPK
inactivation by promoter hypermethylation. We hypothesize
that, in Barrett’s esophagus, some epithelial cells may ac-
quire DAPK CpG island hypermethylation, which 1) leads to
an increased proliferative potential, so that these cells are
vulnerable to additional somatic genome alterations; and 2)
predisposes them to malignant transformation. The possible
protective function of DAPK in the inflammatory process of
reflux esophagitis is supported by the results of a quantitative
real-time reverse transcription PCR analysis performed by
Brabender et al. [25]: This study describes an ‘‘on–off’’
regulation of DAPK during progression to cancer, starting
with significant upregulation of gene expression from normal
esophagus to BE. In a next step, DAPK is significantly
downregulated between BE and BA, which is in line with
the results of our study presented here.
Altered expression of DAPK, presumably caused by
chronic inflammation in the context of reflux esophagitis,
was also observed in tumor-invading macrophages of our
BA samples. Interestingly, hypermethylation of the tumor
epithelium was strongly associated with a marked loss of
DAPK protein expression in macrophages of the tumor
invasion front. We have recently reported a similar ob-
servation for colorectal carcinomas [22], where DAPK hyper-
methylation of tumor cells was strongly associated with
hypermethylation and a decrease in the FASL expression
of macrophages. The methods used in this study cannot
satisfactorily answer the question of whether decreased
DAPK protein expression in macrophages invading BA is
caused by hypermethylation of the macrophages itself or by
signaling between tumor cells and macrophages. Further
studies are needed to address this issue.
In 4 of 20 cases (20%) of the present study, we demon-
strated that CpG island hypermethylation of the DAPK gene
occurs as early as the normally appearing esophageal
squamous mucosa on histologic investigation. This raises
the question as to whether these methylation events repre-
sent normal methylation patterns in non-neoplastic tissues
or whether they reflect methylation changes that predis-
pose to further progression. However, as in the majority of
cases, nondysplastic squamous epithelium was mainly
obtained from areas within a few millimeters’ distance from
Figure 5. Triple immunofluorescence of DAPK and CD68. Triple immunofluorescence of macrophages of BA for the visualization of DAPK (FITC)/CD68 (Texas
red) (original magnification, 10 and 100). Colocalization of DAPK and CD68 in unmethylated BA proves the expression of DAPK protein in tumor-associated
macrophages (A). Enlargement of unmethylated carcinoma shows DAPK clearly confined to the cell membrane, whereas CD68 demonstrates a characteristic
cytoplasmatic appearance within macrophages (B). For methylated BA, only a few DAPK-positive macrophages were observed at the tumor invasion front (C).
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metaplastic/neoplastic lesions and thus located in regions
affected by reflux. Indeed, three of four cases of NTexhibiting
DAPK hypermethylation showed histologic signs of reflux
esophagitis. Furthermore, a significant correlation between
histologic signs of reflux and increased methylation frequen-
cy was confirmed. Therefore, NT tissue with methylation of
DAPK rather seems to reflect epigenetic changes caused
by gastroesophageal reflux and might be at elevated risk for
developing into metaplastic and neoplastic lesions.
A potential criticism of the present analysis is that the
majority of carcinomas investigated for methylation status
were in a very early tumor stage. Therefore, we performed an
immunohistochemical analysis for DAPK protein expression
on a tissue microarray of 66 additional cases of advanced
BA. Here, we could show a significantly weaker DAPK pro-
tein expression in tumor stages III and IV relative to less ad-
vanced stage I and II tumors. This implies, based on our
observation of a correlation between immunohistochemical
expression and MSP analysis, that there might be a general
increase in the frequency of CpG island hypermethylation of
the DAPK promoter with histopathological and clinical pro-
gression of the disease.
This is in line with studies on head, neck, and lung
carcinomas that detected a higher frequency of DAPK pro-
moter hypermethylation for more advanced tumor stages,
lymph node involvement, and increased tumor size [36,37].
Furthermore, promoter hypermethylation of DAPK appeared
to be a significant prognostic factor in primary biliary tract
carcinoma [30]. This increased loss of protein expression
with advanced tumor invasiveness and tumor stage supports
the potential protective function of DAPK against tumor
progression and metastasis in Barrett’s carcinogenesis.
In conclusion, our data demonstrated that CpG island
hypermethylation of DAPK promoter occurs in early-step
lesions and revealed a decrease in protein expression
along the multistep Barrett’s carcinogenesis. Based on the
positive association between a gradual increase in DAPK
hypermethylation, a decrease in protein expression, and
progression of the neoplastic process, we suggest that
inhibition of de novo methylation at any stage could be
important for the prevention of cancer development and
disease progression.
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